MedicicNova Inc. (Nasdaq: MNOV) ended a Phase 2 study of MN-001 early due to extremely positive results and will accelerate further development of MN-001. The stock price climbed $1.93 to close at $12.15.
MediciNova ends Phase 2, accelerates development
April 02, 2018 at 17:56 PM EDT
